Go Pro
→ A “bloodbath” Is Coming (From TradeSmith) (Ad)tc pixel Free KRRO Stock Alerts

Korro Bio (KRRO) Competitors

Korro Bio logo
$10.02 -1.78 (-15.08%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$10.40 +0.38 (+3.83%)
As of 09/18/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

KRRO vs. CTMX, NVCT, MNPR, AURA, and NGNE

Should you buy Korro Bio stock or one of its competitors? Korro Bio's main competitors and comparable companies include CytomX Therapeutics (CTMX), Nuvectis Pharma (NVCT), Monopar Therapeutics (MNPR), Aura Biosciences (AURA), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Korro Bio compare to CytomX Therapeutics?

Korro Bio (NASDAQ:KRRO) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CytomX Therapeutics has a net margin of -435.21% compared to Korro Bio's net margin of -1,834.48%. CytomX Therapeutics' return on equity of -38.46% beat Korro Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Korro Bio-1,834.48% -114.26% -68.57%
CytomX Therapeutics -435.21%-38.46%-30.33%

In the previous week, CytomX Therapeutics had 2 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Korro Bio. CytomX Therapeutics' average media sentiment score of 0.22 beat Korro Bio's score of -0.14 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Korro Bio Neutral
CytomX Therapeutics Neutral

CytomX Therapeutics has higher revenue and earnings than Korro Bio. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$6.39M23.10-$117.26M-$10.00N/A
CytomX Therapeutics$76.20M7.89-$17.37M-$0.50N/A

Korro Bio has a beta of 3.09, indicating that its share price is 209% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

Korro Bio presently has a consensus target price of $16.71, indicating a potential upside of 66.81%. CytomX Therapeutics has a consensus target price of $11.90, indicating a potential upside of 331.16%. Given CytomX Therapeutics' higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Korro Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
2.92
CytomX Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

CytomX Therapeutics beats Korro Bio on 11 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Nuvectis Pharma has higher earnings, but lower revenue than Korro Bio. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvectis PharmaN/AN/A-$26.44M-$1.31N/A
Korro Bio$6.39M23.10-$117.26M-$10.00N/A

Nuvectis Pharma presently has a consensus target price of $36.25, indicating a potential upside of 64.77%. Korro Bio has a consensus target price of $16.71, indicating a potential upside of 66.81%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Nuvectis Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectis Pharma
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Korro Bio
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
2.92

In the previous week, Nuvectis Pharma had 1 more articles in the media than Korro Bio. MarketBeat recorded 2 mentions for Nuvectis Pharma and 1 mentions for Korro Bio. Nuvectis Pharma's average media sentiment score of 0.08 beat Korro Bio's score of -0.14 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company Overall Sentiment
Nuvectis Pharma Neutral
Korro Bio Neutral

Nuvectis Pharma has a beta of -0.26, meaning that its stock price is 126% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.09, meaning that its stock price is 209% more volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Korro Bio's return on equity of -114.26% beat Nuvectis Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvectis PharmaN/A -184.25% -105.24%
Korro Bio -1,834.48%-114.26%-68.57%

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Korro Bio beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Monopar Therapeutics?

Korro Bio (NASDAQ:KRRO) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Korro Bio has a beta of 3.09, meaning that its share price is 209% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Monopar Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Monopar Therapeutics' return on equity of -13.08% beat Korro Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Korro Bio-1,834.48% -114.26% -68.57%
Monopar Therapeutics N/A -13.08%-12.79%

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Monopar Therapeutics has lower revenue, but higher earnings than Korro Bio. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$6.39M23.10-$117.26M-$10.00N/A
Monopar TherapeuticsN/AN/A-$13.72M-$2.17N/A

Korro Bio presently has a consensus price target of $16.71, suggesting a potential upside of 66.81%. Monopar Therapeutics has a consensus price target of $120.08, suggesting a potential upside of 24.48%. Given Korro Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Korro Bio is more favorable than Monopar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
2.92
Monopar Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.86

In the previous week, Monopar Therapeutics had 2 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for Monopar Therapeutics and 1 mentions for Korro Bio. Monopar Therapeutics' average media sentiment score of 0.39 beat Korro Bio's score of -0.14 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Korro Bio Neutral
Monopar Therapeutics Neutral

Summary

Monopar Therapeutics beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.09, indicating that its share price is 209% more volatile than the broader market.

In the previous week, Aura Biosciences and Aura Biosciences both had 1 articles in the media. Aura Biosciences' average media sentiment score of 0.00 beat Korro Bio's score of -0.14 indicating that Aura Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Aura Biosciences Neutral
Korro Bio Neutral

Aura Biosciences presently has a consensus target price of $17.50, suggesting a potential upside of 171.74%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 66.81%. Given Aura Biosciences' higher possible upside, equities analysts plainly believe Aura Biosciences is more favorable than Korro Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Korro Bio
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
2.92

Aura Biosciences has higher earnings, but lower revenue than Korro Bio. Aura Biosciences is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aura BiosciencesN/AN/A-$106.19M-$1.75N/A
Korro Bio$6.39M23.10-$117.26M-$10.00N/A

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -73.18% beat Korro Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Aura BiosciencesN/A -73.18% -62.00%
Korro Bio -1,834.48%-114.26%-68.57%

Summary

Aura Biosciences beats Korro Bio on 8 of the 15 factors compared between the two stocks.

How does Korro Bio compare to Neurogene?

Korro Bio (NASDAQ:KRRO) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Neurogene has lower revenue, but higher earnings than Korro Bio. Neurogene is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Korro Bio$6.39M23.10-$117.26M-$10.00N/A
Neurogene$930K690.45-$90.35M-$5.03N/A

Neurogene has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Neurogene's return on equity of -45.10% beat Korro Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Korro Bio-1,834.48% -114.26% -68.57%
Neurogene N/A -45.10%-41.00%

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Korro Bio presently has a consensus price target of $16.71, indicating a potential upside of 66.81%. Neurogene has a consensus price target of $83.67, indicating a potential upside of 160.73%. Given Neurogene's higher probable upside, analysts clearly believe Neurogene is more favorable than Korro Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Korro Bio
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
2.92
Neurogene
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

In the previous week, Korro Bio and Korro Bio both had 1 articles in the media. Neurogene's average media sentiment score of 1.37 beat Korro Bio's score of -0.14 indicating that Neurogene is being referred to more favorably in the news media.

Company Overall Sentiment
Korro Bio Neutral
Neurogene Positive

Korro Bio has a beta of 3.09, indicating that its share price is 209% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

Summary

Neurogene beats Korro Bio on 10 of the 16 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KRRO vs. The Competition

Export
MetricKorro BioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$147.55M$3.88B$7.24B$12.95B
Dividend YieldN/A3.64%2.57%12.80%
P/E Ratio-1.0014.23275.4925.40
Price / Sales23.101,434.96642.7086.83
Price / CashN/A108.9076.2551.42
Price / Book1.8415.4510.466.33
Net Income-$117.26M-$22.86M$3.49B$358.33M
7 Day Performance-27.44%-1.21%0.59%1.12%
1 Month Performance-22.69%-3.29%-1.74%-2.39%
1 Year Performance-72.21%37.74%18.13%5.35%

Korro Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KRRO
Korro Bio
2.2243 of 5 stars		$10.02
-15.1%		$16.71
+66.8%		-72.2%$147.55M$6.39MN/A57
CTMX
CytomX Therapeutics
2.3449 of 5 stars		$3.65
-1.6%		$11.90
+226.0%		+39.4%$795.33M$18.30MN/A170
NVCT
Nuvectis Pharma
3.6619 of 5 stars		$23.99
-2.0%		$36.25
+51.1%		+250.9%$783.03MN/AN/A8
MNPR
Monopar Therapeutics
2.5058 of 5 stars		$114.38
-2.7%		$118.67
+3.7%		+52.4%$767.49MN/AN/A10
AURA
Aura Biosciences
1.471 of 5 stars		$7.36
-2.6%		$17.50
+137.8%		+5.9%$763.31MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Analyst nicknamed “The Prophet” issues new warning for America
Whitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...
Stansberry Research | Sponsoredtc pixel
NVDA CEO says it’s a "once-in-a-generation opportunity"
NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...
Monument Traders Alliance | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel